DKSH Business Unit Healthcare has announced a strategic partnership with Pfizer (Malaysia) to handle distribution, sales, and marketing for Pfizer’s anti-infectives portfolio across Malaysia.

 

Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments. Under the collaboration, DKSH will oversee end-to-end commercial operations, including warehousing, nationwide distribution, and integrated sales and marketing across all healthcare channels.

 

By combining Pfizer’s scientific innovation with DKSH’s extensive commercial infrastructure and market expertise, the partnership aims to broaden access to essential antimicrobial therapies nationwide. It builds on DKSH’s existing collaborations with Pfizer in Thailand, Taiwan, and Laos, reflecting a shared commitment to improving healthcare access and driving sustainable growth in the region.

 

Deborah Seifert, Cluster Lead – Malaysia, Indonesia, Singapore, Philippines at Pfizer (Malaysia) Sdn. Bhd., said: “At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We are pleased to continue to work with DKSH as a strategic partner to expand access to our anti-infective portfolio, supporting healthcare professionals with reliable, high-quality treatment options that address serious infectious diseases.”

 

Sandeep Tewari, Vice President, Healthcare and Head, Country Leadership, Malaysia, DKSH, added: “This partnership reflects our shared commitment to improving patient outcomes by ensuring timely access to innovative and essential antimicrobial therapies. By combining Pfizer’s strong scientific leadership with DKSH’s proven commercial capabilities and extensive distribution network, we aim to deliver greater value to healthcare providers and patients nationwide, providing better healthcare for all.”

 

Together, DKSH Malaysia and Pfizer are working to strengthen infection management in Malaysia and advance patient care through timely access to critical therapies.